MILabs

MILabs is a biotechnology company founded in 2006, specializing in high-performance preclinical SPECT, PET, CT, and Optical Imaging systems for molecular and in vivo imaging research. The company's 4x4D multimodal imaging technology, equipped with four-dimensional imaging capabilities, empowers researchers to enhance diagnostics and therapy development through complementary, data-rich, co-registered images. Each modality by itself offers data beyond the capabilities of any other stand-alone system. With over 300 imaging modules installed worldwide, MILabs collaborates with leading universities, hospitals, contract research organizations, and pharmaceutical companies, contributing significantly to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac, and neurodegenerative diseases. The company received a Venture Round investment from Thuja Capital on 11 October 2016. MILabs' mission is to make molecular imaging clear and support a wide range of imaging research programs with continuous innovation and dedicated service. For more information, visit www.milabs.com.